{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/menorrhagia/prescribing-information/oral-norethisterone/","result":{"pageContext":{"chapter":{"id":"0e5ebc73-f73e-5d12-9e9a-82f8373fc507","slug":"oral-norethisterone","fullItemName":"Oral norethisterone","depth":2,"htmlHeader":"<!-- begin field 9a2c886c-340f-44c2-86a5-e82a6a0b8a8b --><h2>Oral norethisterone</h2><!-- end field 9a2c886c-340f-44c2-86a5-e82a6a0b8a8b -->","summary":"","htmlStringContent":"<!-- begin item c25e0e0e-9cae-4c58-865a-13db29b048da --><!-- end item c25e0e0e-9cae-4c58-865a-13db29b048da -->","topic":{"id":"d4abfe41-b89f-5d51-8168-7ff98b4290f9","topicId":"4013d716-0ba5-4984-bfb1-8c7eca832ba8","topicName":"Menorrhagia","slug":"menorrhagia","lastRevised":"Last revised in December 2018","chapters":[{"id":"0e4b035a-9880-5848-b317-d92515f750d7","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"98c45e96-1179-53a4-9b74-a5f71fffaebd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"73a36e11-2419-5f1f-9d0a-989641466fbf","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"49315340-c2d5-5025-a18d-ab2347baae5b","slug":"changes","fullItemName":"Changes"},{"id":"a232dfd0-a500-5e6b-9ead-3c3c94f0d2cf","slug":"update","fullItemName":"Update"}]},{"id":"cdc50c06-ff06-509a-be3e-1047ea50bc07","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"e5043cba-12e2-5f47-aac7-4e74d516a7fa","slug":"goals","fullItemName":"Goals"},{"id":"b1ea37fe-6d24-5529-9f7e-c0e49ccba796","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cf03761e-6677-5ba5-ac47-f290b7cb66ec","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"24f740a2-df74-5305-b364-52d1fa68040a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"913b3856-8846-53a2-86c7-f489c766e0f4","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"45c06974-d676-5c1e-bc8f-269a8c65df4f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7d698fba-d82e-55be-bcc0-0ee11398e628","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"aa066829-e43c-5a83-b602-2680d838463a","slug":"definition","fullItemName":"Definition"},{"id":"37436c25-6db1-5e7c-b8fd-7590cd5ca25d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e5c102c5-46d5-5096-bb8b-d2ef0960e353","slug":"causes","fullItemName":"Causes"},{"id":"b7f926cd-7de3-5b25-9697-78920cccf7b7","slug":"complications","fullItemName":"Complications"}]},{"id":"305d1c2b-5b47-5eda-adc5-03782afe2229","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"fc278e0b-a1a4-54d5-b44c-ddde104596ea","slug":"assessment","fullItemName":"Assessment"},{"id":"1d41d3f0-3049-510f-982a-9d9c39c5d52f","slug":"investigations-for-the-cause-of-menorrhagia","fullItemName":"Investigations for the cause of menorrhagia"}]},{"id":"5c051ed4-4e95-59b7-8bf1-c9e426198f5f","fullItemName":"Management","slug":"management","subChapters":[{"id":"e30d2783-35fc-5470-9fb3-b8a643f83450","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"324cd8d0-2857-5c2b-bd8e-ac2d83c5b55d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c6b368dc-8409-55ee-8072-ffa3dc54a6f0","slug":"tranexamic-acid","fullItemName":"Tranexamic acid"},{"id":"13dd98d9-6054-5177-8564-df8c7ede9e5c","slug":"nonsteroidal-anti-inflammatory-drugs","fullItemName":"Nonsteroidal anti-inflammatory drugs"},{"id":"0e5ebc73-f73e-5d12-9e9a-82f8373fc507","slug":"oral-norethisterone","fullItemName":"Oral norethisterone"}]},{"id":"5964d183-6ca2-5e15-9a46-bd0c666e6146","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"443b20d0-895a-5b92-810b-17af26ab31e6","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"93531fdf-665e-5277-9d61-5b62984a866f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"949f5d38-0e7a-59b8-a641-b1096ac7f3b3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"dd5aaa9a-b897-51a6-b133-d7e4170711df","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"81610614-c77a-5340-b5b3-721aafb19cc3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"83d1c27f-0003-5757-b8a1-90f777106d61","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8fe218e8-4e7d-55af-9b5b-4f2bad344402","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"324cd8d0-2857-5c2b-bd8e-ac2d83c5b55d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"a3dde45c-9c33-5120-810f-48e18c752997","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 47d5655b-9609-48a1-b66f-3f6d7aafc9cd --><h3>Dose</h3><!-- end field 47d5655b-9609-48a1-b66f-3f6d7aafc9cd -->","summary":"","htmlStringContent":"<!-- begin item b7fd9d31-6597-401f-81d7-b756614bfc7d --><!-- begin field 126a25ac-0db5-4bc5-9fc2-bec671c5c954 --><ul><li>Prescribe oral norethisterone (5 mg three times daily) from days 5–26 of the menstrual cycle (the follicular and luteal phases) — this dose is off-label.<ul><li>The licensed regimen, used only during the luteal phase (days 19–26), is no longer recommended as it is ineffective.</li></ul></li><li>Norethisterone should be taken for a minimum of 3 months, but preferably 6 months, before referral if symptoms have not improved.</li><li>Higher doses are recommended if the woman has severe acute heavy menstrual bleeding.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">IOG, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">NICE, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">ABPI, 2017b</a>]</p><!-- end field 126a25ac-0db5-4bc5-9fc2-bec671c5c954 --><!-- end item b7fd9d31-6597-401f-81d7-b756614bfc7d -->","subChapters":[]},{"id":"62994824-bb90-56c8-a695-c5bbed2ac345","slug":"contraindications","fullItemName":"Contraindications","depth":3,"htmlHeader":"<!-- begin field 55162479-2455-4dbc-bf54-8d454a783335 --><h3>Contraindications and cautions</h3><!-- end field 55162479-2455-4dbc-bf54-8d454a783335 -->","summary":"","htmlStringContent":"<!-- begin item 362404dd-7294-4f64-9d87-86fc7eda2ce8 --><!-- begin field d2209a5d-d409-4f83-8327-9e322c2161f9 --><ul><li>Do not prescribe norethisterone to women who are pregnant, or those with:<ul><li>A history of, or predisposition to, thromboembolism.</li><li>Liver cancer.</li><li>Genital or breast cancer (unless progestogens are being used in the management of these conditions).</li><li>Severe arterial disease.</li><li>Undiagnosed vaginal bleeding.</li><li>Acute porphyria.</li><li>A history during pregnancy of idiopathic jaundice, severe pruritus, or pemphigoid gestationis.</li></ul></li><li>Prescribe norethisterone with caution to women:<ul><li>With a history of depression. </li><li>With hypertension.</li><li>Who have conditions that can be aggravated by fluid retention, including: <ul><li>Epilepsy.</li><li>Migraine.</li><li>Asthma.</li><li>Cardiac dysfunction.</li><li>Renal dysfunction.</li><li>Asthma.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">BNF 73, 2017</a>]</p><!-- end field d2209a5d-d409-4f83-8327-9e322c2161f9 --><!-- end item 362404dd-7294-4f64-9d87-86fc7eda2ce8 -->","subChapters":[]},{"id":"96d428d2-8a95-5e42-b14c-297cbd61b304","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 572e4e7c-20f2-405f-8005-2a9a067e5990 --><h3>Adverse effects</h3><!-- end field 572e4e7c-20f2-405f-8005-2a9a067e5990 -->","summary":"","htmlStringContent":"<!-- begin item 4efeefad-9287-462e-bb06-1bcdc3f95e7e --><!-- begin field 31effbf6-093b-4b5f-a136-8cd374098d22 --><ul><li>Possible adverse effects of norethisterone include: <ul><li><strong>Gastrointestinal disorders </strong>— nausea (common), vomiting.</li><li><strong>Hepatobiliary disorders </strong>—<strong> </strong>cholestatic jaundice.</li><li><strong>Immune system disorders </strong>— anaphylaxis and anaphylactoid reactions, angioedema.</li><li><strong>Metabolism and nutrition disorders </strong>— weight gain (common).</li><li><strong>Nervous system disorders </strong>— depression (rare), headache (common), dizziness, insomnia.</li><li><strong>Skin and subcutaneous disorders </strong>— acne (common), hirsutism, rash, urticaria, oedema, fluid retention, bloating (common).</li><li><strong>Reproductive system disorders </strong>— menstrual disturbances, breast tenderness (common).  </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">Micromedex, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">NICE, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">ABPI, 2017b</a>] </p><!-- end field 31effbf6-093b-4b5f-a136-8cd374098d22 --><!-- end item 4efeefad-9287-462e-bb06-1bcdc3f95e7e -->","subChapters":[]},{"id":"1a29ad1a-8c6f-52e2-9bf8-9bf98939d558","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 3efa1637-0b4a-4e62-a6b4-a7a20070ab08 --><h3>Drug interactions</h3><!-- end field 3efa1637-0b4a-4e62-a6b4-a7a20070ab08 -->","summary":"","htmlStringContent":"<!-- begin item 0f706a3a-4b66-428d-a92c-a7a20070a934 --><!-- begin field 364a528b-0aaf-4cb6-b74f-a7a20070ab08 --><ul><li>Drug interactions may occur with liver enzyme-inducing drugs:<ul><li>Antibiotics — rifampicin and rifabutin.</li><li>Antiepileptics — carbamazepine, oxcarbazepine, phenytoin, barbiturates, primidone, and topiramate. Topiramate is associated with a risk of fetal malformations and can impair the effectiveness of hormonal contraceptives. Before initiating topiramate in a woman of childbearing potential, pregnancy testing should be performed. The patient should be fully informed of the risks related to the use of topiramate during pregnancy. Ensure that women and girls of childbearing potential are advised that they should be using a highly effective method of contraception. Topiramate is a weak enzyme inducer, but the contraceptive efficacy of the COC may be unaffected by topiramate doses lower than 200 mg daily.</li><li>Antiretrovirals — ritonavir, ritonavir-boosted protease inhibitors, efavirenz, and nevirapine.</li><li>St John's wort.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">ABPI, 2017c</a>] </p><!-- end field 364a528b-0aaf-4cb6-b74f-a7a20070ab08 --><!-- end item 0f706a3a-4b66-428d-a92c-a7a20070a934 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}